Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
about
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesA microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisTherapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacyAntiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis.Targeted therapies for adrenocortical carcinoma: IGF and beyond.Radioimmunotherapy with α-particle-emitting radionuclides.Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapyDual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxiaInhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor ModelsDistribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer ModelExtracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy(18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.Actinium-225 in targeted alpha-particle therapeutic applications.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.Tumor vascular microenvironment determines responsiveness to photodynamic therapy.Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.Structure and properties of DOTA-chelated radiopharmaceuticals within the Ac decay pathway
P2860
Q26828930-108117CE-6E77-4BC2-8649-6C94451FCE75Q30540674-4E36C34D-A7DB-4BBD-9654-4CC967F4CB13Q33765417-13B76C91-9D70-4F54-9140-CC06C7A05321Q33912305-F4E2874E-4549-4489-B4C5-0283431558B9Q34101433-D6B84B21-53C8-4543-B568-E04D1B6827BDQ34419562-DE75F8B2-5108-4CA3-837D-EFC4C0640C62Q35078406-BF3678A9-AA25-417E-A6DB-D09798AC49E7Q35523959-149E8FA0-4A66-4972-A95C-EC06AEAE9F85Q35552373-6D64AFB7-FB89-4710-9CD0-D40F6B76F0DCQ35751307-5CBBA5F4-5F21-489C-84D2-85BD8EBC62C7Q36100135-C52E4490-3FC5-4991-AB28-ED257D38FBE4Q36334121-4309555A-D071-4BAD-AD2E-4AE8EDBF1157Q36417444-787EB297-748C-4214-B645-4FF528D2C022Q36447756-382AC51D-F0C0-4AD1-BD1A-9283C4B4912AQ36653033-FB40D08C-E178-456A-9FBB-22DA68B42325Q36676175-E24C601E-5371-4441-AF07-834530AAF1F1Q36782265-C02AA2E4-8AA1-4414-818A-6F07ADE3BEBCQ37309920-1B26B99A-191D-469D-A98C-DED543829BE9Q37389371-AD673AAF-44CF-431D-A4EE-E4C18DCABEFAQ37517611-1B723366-FE46-4AC1-BCC8-B9FD0DE78F5EQ37587264-5369D5F5-8018-4E2E-AEB8-EE3E89551542Q37971807-8B404EF8-56DA-4677-A1E8-5D966711409CQ38150356-21587D90-A35A-45AC-9CE9-C7C350304C02Q38155510-98F178BE-6DCD-439C-83E3-B355B04735E5Q38217457-0DBBD3C7-176D-4B75-8AF2-ABA726AA4F9FQ39257411-952647A0-9182-4FAC-B5BF-8E09F2FA351DQ39388400-F2F4EE1F-1624-42DD-9030-8F1120EE15F7Q39413582-60AD401E-6531-44D4-9D11-252AAAAB4262Q41099763-F79A2B3A-C8F6-415B-8DDB-F4CF9DDE471AQ42483948-DECFFF0F-951E-42FD-A935-9A4E9F8F9F66Q57179186-EE630AE3-BF32-4D21-ADDE-5F0F1336077B
P2860
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@ast
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@en
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@nl
type
label
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@ast
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@en
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@nl
prefLabel
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@ast
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@en
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@nl
P2093
P2860
P1433
P1476
Selective killing of tumor neo ...... emotherapy delivery to tumors.
@en
P2093
Carlos H Villa
David A Scheinberg
Erik Henke
Freddy E Escorcia
Michael R McDevitt
Peter Smith-Jones
Robert Benezra
Ronald G Blasberg
P2860
P304
P356
10.1158/0008-5472.CAN-10-2029
P407
P577
2010-11-02T00:00:00Z